Effective for dates of service on and after November 1, 2021, the following current clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.


For Anthem Blue Cross and Blue Shield and affiliate HealthKeepers, Inc., prior authorization of these specialty pharmacy drugs will be managed by Anthem. Drugs used for the treatment of Oncology will still require prior authorization by AIM Specialty Health® (AIM), a separate company.  This applies to members with Preferred Provider Organization (PPO), Anthem HealthKeepers (HMO), POS AdvantageOne, and Act Wise (CDH plans).


Access the clinical criteria document information.


  • ING-CC-0107 Bevacizumab for Non-Ophthalmologic Indications
  • ING-CC-0124 Keytruda (pembrolizumab)
  • ING-CC-0128 Tecentriq (atezolizumab)
  • ING-CC-0160 Vyepti (eptinezumab)
  • ING-CC-0198 Relizorb (immobilized lipase) cartridge



Featured In:
August 2021 Anthem Provider News - Virginia